M.T.E.-6 CONCENTRATED 5 MG
ZINC (ZINC SULFATE) : 5 MG COPPER (CUPRIC SULFATE) : 1 MG CHROMIUM (CHROMIC CHLORIDE) : 10 MCG MANGANESE (MANGANESE SULFATE) : 0.5 MG SELENIUM (SELENIOUS ACID) : 60 MCG IODIDE (SODIUM IODIDE) : 75 MCG · DIN 02139235 · PHARMACEUTICAL PARTNERS OF CANADA INC
Health Canada status: CANCELLED POST MARKET
What is M.T.E.-6 CONCENTRATED?
M.T.E.-6 CONCENTRATED 5 MG contains ZINC (ZINC SULFATE) : 5 MG COPPER (CUPRIC SULFATE) : 1 MG CHROMIUM (CHROMIC CHLORIDE) : 10 MCG MANGANESE (MANGANESE SULFATE) : 0.5 MG SELENIUM (SELENIOUS ACID) : 60 MCG IODIDE (SODIUM IODIDE) : 75 MCG. It is listed in the Health Canada Drug Product Database under DIN 02139235, held by PHARMACEUTICAL PARTNERS OF CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 15-Feb-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is M.T.E.-6 CONCENTRATED used for?
M.T.E.®-6 CONCENTRATED is indicated for use as a supplement to intravenous solutions given for TPN. It’s administration in TPN solutions help to maintain plasma zinc, copper, manganese, chromium, iodide and selenium levels and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02139235 |
|---|---|
| Brand name | M.T.E.-6 CONCENTRATED |
| Generic / active ingredient | ZINC (ZINC SULFATE) : 5 MG COPPER (CUPRIC SULFATE) : 1 MG CHROMIUM (CHROMIC CHLORIDE) : 10 MCG MANGANESE (MANGANESE SULFATE) : 0.5 MG SELENIUM (SELENIOUS ACID) : 60 MCG IODIDE (SODIUM IODIDE) : 75 MCG |
| Manufacturer | PHARMACEUTICAL PARTNERS OF CANADA INC |
| Strength | 5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XA30 COMBINATIONS OF ELECTROLYTES |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 15-Feb-2008 |
| Original market date | 1996-09-10 00:00:00 |
How is it stored and handled?
Store between 15 to 30°C (59 to 86°F). Do not permit to freeze.
How is it supplied?
1 mL single-dose, flip-top, glass vials in boxes of 25 vials; 10 mL multi-dose, flip-top, glass vials in boxes of 10 vials
What can be used instead?
Other Canadian products sharing ATC code B05XA30 COMBINATIONS OF ELECTROLYTES. 1 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TPN ELECTROLYTES | 16.55 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00590215 |
| CARBICARB INJECTION | 35 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00757004 |
| HYPERLYTE (MULTI-ELECTROLYTE CONCENTRATE) | 690 MG / 25 ML | LIQUID | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | DIN 01963910 |
| LYPHOLYTE | 2.5 G / 20 ML | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | DIN 02139618 |
| LYPHOLYTE MULTI-ELECTROLYTE CONC INJ | 43 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 01944940 |
| M.T.E.-4 | 1 MG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | DIN 02139278 |
| M.T.E.-4 CONCENTRATED | 10 MCG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | DIN 02139251 |
| MTE 4 INJ | 1 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 01945319 |
| MULTIPLE ELECTROLYTE ADDITIVE INJ | 29.8 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00421952 |
Who else supplies COMBINATIONS OF ELECTROLYTES worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS OF ELECTROLYTES appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.